title: [Initial and unique treatment of macular edema due to branch retinal vein occlusion with antiangiogenic agents. A comparative pilot study].
authors.forename: R
authors.initials: R
authors.lastname: Gallego-Pinazo
authors.forename: E
authors.initials: E
authors.lastname: Francés
authors.forename: M J
authors.initials: MJ
authors.lastname: Gómez
authors.forename: R
authors.initials: R
authors.lastname: López
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Llopis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D010865:Pilot Projects; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C495058:pegaptanib; D000069579:Ranibizumab